Trial Profile
A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Novartis
- 06 Oct 2011 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
- 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.